The U.S. Food and Drug Administration has expanded the approved use of Addyi (flibanserin) to include the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women up to age 65. Previously, Addyi was approved only for premenopausal women.
HSDD is defined as a persistently low sexual desire that causes distress or interpersonal difficulties, which affects many postmenopausal women. Addyi works by targeting brain chemistry — balancing neurotransmitters like dopamine, norepinephrine, and serotonin — rather than acting as a hormone therapy. This non-hormonal approach may offer a new option for women who cannot or do not want to use hormone-based treatments.
This provides Dr. Hamori and Dr. DiEdwardo with additional options to treat patients with their women's wellness and/or hormone replacement therapies. Call to schedule a consultation and to learn more about Addyi.
Christine Hamori Cosmetic Surgery + Skin Spa113 Tremont Street, Duxbury, Massachusetts, 02332
Call us: 781-934-2200
Serving Boston's South Shore, Cape Cod and Beyond
Posts
